CurvaFix

CurvaFix, Inc. is a privately held medical device company headquartered in Bellevue, Washington that develops implantable products to improve fracture repair in curved bones, with an initial focus on fragility fractures of the pelvis (FFP) and high-energy and low-impact traumatic pelvic fractures. Its flagship product line is the CurvaFix IM Implant, a curved intramedullary nail that follows the natural contours of pelvic bone, and the next-generation CurvaFix Low Profile intramedullary nailing system for the pelvis. The implants have received 510(k) clearance from the U.S. Food and Drug Administration and are cleared for use only within the United States.

The device consists of interlocking segments that remain flexible during insertion over a steerable, ball-tipped guide wire and then lock to become rigid once positioned. The company markets the approach as providing stronger, more stable fixation than straight screws and bone plates in fragile and dysmorphic bone, potentially reducing pain and allowing earlier mobility through a minimally invasive procedure. A 9.5 mm implant launched in late 2021 and a smaller 7.5 mm implant, cleared by FDA in November 2022 and launched in February 2023, extends use to small-boned patients.

The company frames its market around an estimated 200,000 U.S. pelvic fractures annually, growing roughly 9% per year with population aging; it cites 186,000 U.S. pelvic fracture hospitalizations in 2019, including 108,000 geriatric fractures, and estimates over 150,000 geriatric pelvic fractures in 2023, about 80% in women. It notes that only about 10% of FFP patients currently receive surgery, versus about 95% of hip fracture patients.